Hualan Biological Bacterin Inc. (301207.SZ) develops, manufactures and markets human vaccines with a focus on influenza, meningococcal and hepatitis B immunizations. The company offers Influenza Vaccine (Split Virion), Inactivated (Adult and Children); Influenza Vaccine (Split Virion), Inactivated, Quadrivalent (Adult, in vial and prefilled syringe formats); Group A and C Meningococcal Polysaccharide Vaccine; Group ACYW135 Meningococcal Polysaccharide Vaccine; and Recombinant Hepatitis B Vaccine (Hansenula Polymorpha, 10µg in 0.5mL vial and prefilled syringe formats). Founded in 2005 and headquartered at No. 1-1 Hualan Avenue, Xinxiang City, Henan Province, China, it operates primarily in the biopharmaceutical sector targeting domestic and international markets including Asia, Europe, the Americas and Ukraine. A holding subsidiary of Hualan Biological Engineering Inc., it pioneered the world's first marketed Influenza A (H1N1) Vaccine in 2009 and became the first Chinese influenza vaccine producer to receive WHO prequalification. Recent developments include a strategic partnership with Russia's Pharmasyntez announced in October 2025 for joint drug development, technology transfer and localized production of therapeutic monoclonal antibodies at Pharmasyntez facilities.